Reolysin-Taxol Combo Increases Breast Cancer Patients’ Survival Rate – Immuno-Oncology News
Immuno-Oncology News |
Reolysin-Taxol Combo Increases Breast Cancer Patients' Survival Rate
Immuno-Oncology News Oncolytics Biotech is partnering with other companies to develop immunotherapy and immunomodulatory applications for Reolysin, which improved breast cancer survival rates. A combination of Reolysin and the chemotherapy Taxol (paclitaxel) increased … |
